Asia · Markets & Finance · SCMP Business

US firm ArriVent’s plunge shows risks facing China’s biotech expansion into global markets

Published by SCMP Business · Hong Kong 2 h ago

US firm ArriVent BioPharma’s shares plummeted after a late-stage trial failure involving a cancer drug licensed from China, a setback that analysts said highlighted the challenges…

Read the full article on SCMP Business Sign in to save

MediaNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.scmp.com)

Also worth reading

The Business Times

US firm ArriVent’s plunge shows risks facing China’s biotech expansion into global markets

Share

Also worth reading

Indonesia’s IPOs slow to a trickle after regulator raises listing bar

DMK slams RaGa over silence on TN voter deletions

Indian medtech startup Sunfox raises $7m

Why parents need to be involved in the money conversation with their children

Tesla, BYD account for four in 10 imported cars sold in Korea

Korean investors suffer $1.7 billion losses from leveraged ETFs